181 related articles for article (PubMed ID: 34695176)
1. Two novel high-risk adult B-cell acute lymphoblastic leukemia subtypes with high expression of CDX2 and IDH1/2 mutations.
Yasuda T; Sanada M; Kawazu M; Kojima S; Tsuzuki S; Ueno H; Iwamoto E; Iijima-Yamashita Y; Yamada T; Kanamori T; Nishimura R; Kuwatsuka Y; Takada S; Tanaka M; Ota S; Dobashi N; Yamazaki E; Hirose A; Murayama T; Sumi M; Sato S; Tange N; Nakamura Y; Katsuoka Y; Sakaida E; Kawamata T; Iida H; Shiraishi Y; Nannya Y; Ogawa S; Taniwaki M; Asou N; Hatta Y; Kiyoi H; Matsumura I; Horibe K; Mano H; Naoe T; Miyazaki Y; Hayakawa F
Blood; 2022 Mar; 139(12):1850-1862. PubMed ID: 34695176
[TBL] [Abstract][Full Text] [Related]
2. Enhancer retargeting of CDX2 and UBTF::ATXN7L3 define a subtype of high-risk B-progenitor acute lymphoblastic leukemia.
Kimura S; Montefiori L; Iacobucci I; Zhao Y; Gao Q; Paietta EM; Haferlach C; Laird AD; Mead PE; Gu Z; Stock W; Litzow M; Rowe JM; Luger SM; Hunger SP; Ryland GL; Schmidt B; Ekert PG; Oshlack A; Grimmond SM; Rehn J; Breen J; Yeung D; White DL; Aldoss I; Jabbour EJ; Pui CH; Meggendorfer M; Walter W; Kern W; Haferlach T; Brady S; Zhang J; Roberts KG; Blombery P; Mullighan CG
Blood; 2022 Jun; 139(24):3519-3531. PubMed ID: 35192684
[TBL] [Abstract][Full Text] [Related]
3. Oncogenetic landscape and clinical impact of IDH1 and IDH2 mutations in T-ALL.
Simonin M; Schmidt A; Bontoux C; Dourthe MÉ; Lengliné E; Andrieu GP; Lhermitte L; Graux C; Grardel N; Cayuela JM; Huguet F; Arnoux I; Ducassou S; Macintyre E; Gandemer V; Dombret H; Petit A; Ifrah N; Baruchel A; Boissel N; Asnafi V
J Hematol Oncol; 2021 May; 14(1):74. PubMed ID: 33941203
[TBL] [Abstract][Full Text] [Related]
4. Molecular alterations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) metabolic genes and additional genetic mutations in newly diagnosed acute myeloid leukemia patients.
Chotirat S; Thongnoppakhun W; Promsuwicha O; Boonthimat C; Auewarakul CU
J Hematol Oncol; 2012 Mar; 5():5. PubMed ID: 22397365
[TBL] [Abstract][Full Text] [Related]
5. Type and location of isocitrate dehydrogenase mutations influence clinical characteristics and disease outcome of acute myeloid leukemia.
Koszarska M; Bors A; Feczko A; Meggyesi N; Batai A; Csomor J; Adam E; Kozma A; Orban TI; Lovas N; Sipos A; Karaszi E; Dolgos J; Fekete S; Reichardt J; Lehoczky E; Masszi T; Tordai A; Andrikovics H
Leuk Lymphoma; 2013 May; 54(5):1028-35. PubMed ID: 23039322
[TBL] [Abstract][Full Text] [Related]
6. Mutation analysis of isocitrate dehydrogenase in acute lymphoblastic leukemia.
Zhang Y; Wei H; Tang K; Lin D; Zhang C; Mi Y; Wang L; Wang C; Wang M; Wang J
Genet Test Mol Biomarkers; 2012 Aug; 16(8):991-5. PubMed ID: 22809434
[TBL] [Abstract][Full Text] [Related]
7. IDH1 and IDH2 mutations in pediatric acute leukemia.
Andersson AK; Miller DW; Lynch JA; Lemoff AS; Cai Z; Pounds SB; Radtke I; Yan B; Schuetz JD; Rubnitz JE; Ribeiro RC; Raimondi SC; Zhang J; Mullighan CG; Shurtleff SA; Schulman BA; Downing JR
Leukemia; 2011 Oct; 25(10):1570-7. PubMed ID: 21647154
[TBL] [Abstract][Full Text] [Related]
8. Prevalence and Clinical Effect of IDH1 and IDH2 Mutations Among Cytogenetically Normal Acute Myeloid Leukemia Patients.
Aref S; Kamel Areida el S; Abdel Aaal MF; Adam OM; El-Ghonemy MS; El-Baiomy MA; Zeid TA
Clin Lymphoma Myeloma Leuk; 2015 Sep; 15(9):550-5. PubMed ID: 26189213
[TBL] [Abstract][Full Text] [Related]
9. Concurrent CDX2 cis-deregulation and UBTF::ATXN7L3 fusion define a novel high-risk subtype of B-cell ALL.
Passet M; Kim R; Gachet S; Sigaux F; Chaumeil J; Galland A; Sexton T; Quentin S; Hernandez L; Larcher L; Bergugnat H; Ye T; Karasu N; Caye A; Heizmann B; Duluc I; Chevallier P; Rousselot P; Huguet F; Leguay T; Hunault M; Pflumio F; Freund JN; Lobry C; Lhéritier V; Dombret H; Domon-Dell C; Soulier J; Boissel N; Clappier E
Blood; 2022 Jun; 139(24):3505-3518. PubMed ID: 35316324
[TBL] [Abstract][Full Text] [Related]
10. Oncogenic lesions and molecular subtypes in adults with B-cell acute lymphoblastic leukemia.
Yasuda T; Sanada M; Tsuzuki S; Hayakawa F
Cancer Sci; 2023 Jan; 114(1):8-15. PubMed ID: 36106363
[TBL] [Abstract][Full Text] [Related]
11. Isocitrate dehydrogenase mutation hot spots in acute lymphoblastic leukemia and oral cancer.
Tang JY; Chang CC; Lin PC; Chang JG
Kaohsiung J Med Sci; 2012 Mar; 28(3):138-44. PubMed ID: 22385606
[TBL] [Abstract][Full Text] [Related]
12. Acquired mutations in the genes encoding IDH1 and IDH2 both are recurrent aberrations in acute myeloid leukemia: prevalence and prognostic value.
Abbas S; Lugthart S; Kavelaars FG; Schelen A; Koenders JE; Zeilemaker A; van Putten WJ; Rijneveld AW; Löwenberg B; Valk PJ
Blood; 2010 Sep; 116(12):2122-6. PubMed ID: 20538800
[TBL] [Abstract][Full Text] [Related]
13. IDH1 and IDH2 mutations are frequent genetic alterations in acute myeloid leukemia and confer adverse prognosis in cytogenetically normal acute myeloid leukemia with NPM1 mutation without FLT3 internal tandem duplication.
Paschka P; Schlenk RF; Gaidzik VI; Habdank M; Krönke J; Bullinger L; Späth D; Kayser S; Zucknick M; Götze K; Horst HA; Germing U; Döhner H; Döhner K
J Clin Oncol; 2010 Aug; 28(22):3636-43. PubMed ID: 20567020
[TBL] [Abstract][Full Text] [Related]
14. Genomic Profiling of Adult and Pediatric B-cell Acute Lymphoblastic Leukemia.
Liu YF; Wang BY; Zhang WN; Huang JY; Li BS; Zhang M; Jiang L; Li JF; Wang MJ; Dai YJ; Zhang ZG; Wang Q; Kong J; Chen B; Zhu YM; Weng XQ; Shen ZX; Li JM; Wang J; Yan XJ; Li Y; Liang YM; Liu L; Chen XQ; Zhang WG; Yan JS; Hu JD; Shen SH; Chen J; Gu LJ; Pei D; Li Y; Wu G; Zhou X; Ren RB; Cheng C; Yang JJ; Wang KK; Wang SY; Zhang J; Mi JQ; Pui CH; Tang JY; Chen Z; Chen SJ
EBioMedicine; 2016 Jun; 8():173-183. PubMed ID: 27428428
[TBL] [Abstract][Full Text] [Related]
15. IDH1 Mutation Is an Independent Inferior Prognostic Indicator for Patients with Myelodysplastic Syndromes.
Wang N; Wang F; Shan N; Sui X; Xu H
Acta Haematol; 2017; 138(3):143-151. PubMed ID: 28873367
[TBL] [Abstract][Full Text] [Related]
16. Genomic landscape of pediatric B-other acute lymphoblastic leukemia in a consecutive European cohort.
Zaliova M; Stuchly J; Winkowska L; Musilova A; Fiser K; Slamova M; Starkova J; Vaskova M; Hrusak O; Sramkova L; Stary J; Zuna J; Trka J
Haematologica; 2019 Jul; 104(7):1396-1406. PubMed ID: 30630978
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of IDH1 and IDH2 mutations in patients with acute myeloid leukemia].
Jia ZX; Zhou M; Chao HY; Lu XZ; Zhang R; Cen L; Xiao R; Jiang NK
Zhonghua Xue Ye Xue Za Zhi; 2012 May; 33(5):397-401. PubMed ID: 22781800
[TBL] [Abstract][Full Text] [Related]
18. Additional mutations in IDH1/2-mutated patients with acute myeloid leukemia.
Lu J; Chen M; Hua H; Qin W; Zhang R; Lu X; Chao H
Int J Lab Hematol; 2021 Dec; 43(6):1483-1490. PubMed ID: 34270876
[TBL] [Abstract][Full Text] [Related]
19. [IDH1 Gene Mutation and Its Clinical Significance in patients with Acute Myeloid Leukemia].
Wei JF; Qiu HY; Chen GH; Wang Y; Chen Z; Liu HJ; Mao JP; Jia T; Xue LG; Cai ZM; Zhu YX; Zhao LD
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2015 Oct; 23(5):1252-7. PubMed ID: 26524018
[TBL] [Abstract][Full Text] [Related]
20. IDH1 and IDH2 mutations in patients with acute myeloid leukemia: Suitable targets for minimal residual disease monitoring?
Petrova L; Vrbacky F; Lanska M; Zavrelova A; Zak P; Hrochova K
Clin Biochem; 2018 Nov; 61():34-39. PubMed ID: 30176240
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
